Table 2.
Categories of classification system | Criteria of classification system | Terms used in articles |
---|---|---|
A-Health outcomes and benefits of intervention |
Number of criteria: 6 |
Number of terms: 44 |
A1: Health benefits: 7 terms, cited 10 times |
· A1 – health benefits
[13,31,38,50], potential health gain
[44], enhanced health outcomes
[44], relative advantage
[51], health effects
[30], additional effects
[22], incremental health gain
[43] |
|
A2: Efficacy/effectiveness: 11 terms, cited 29 times |
· A2 – efficacy
[13,47], efficacy/effectiveness
[10,19,20,25,27,28,44,48], effectiveness
[14,22,26,32-34,48], clinical benefit
[19,22,24,42,47], clinical impact
[45], clinical merit
[22], relative clinical benefit in relation with current standards
[16], determine relative value for degree of benefit against benchmarks
[16], magnitude of treatment effect
[22], response rate
[43], onset and duration of treatment/program effect
[43] |
|
A3: Life saving: 4 terms, cited 5 times |
· A3 – prolongation of disease-free survival
[42], saving life
[19], life expectancy gains
[13], average life-year benefit per patient
[13,33] |
|
A4: Safety: 11 terms, 19 times |
· A4 – side effects
[33,41,47], unintended consequences
[40], safety
[9,22,26,31], safety and tolerability
[10,19,20], risks
[20,22], risk management
[44], harm
[42], adverse effects
[32], inconvenience
[22], risk of event
[22], reduction in symptomatic toxicity compared with standard therapy
[42] |
|
A5: PRO: 10 terms, 17 times |
· A5 – patients reported outcomes
[10], quality of life
[19,42,44,52], impact on quality of life
[22,43], number of QALYs gained per patient
[36,39], disability adjusted life years
[13], likely impact on patient
[16], patient preference
[25], patient autonomy
[26,35,40], relative value to patient
[16], best for patient
[38] |
|
A6: Quality of care: 1 term, 1 time |
· A6 – overall gain in quality of care
[44] |
|
B-Type of health benefit |
Number of criteria: 2 |
Number of terms: 12 |
B1: Population effect (prevention): 6 terms, 11 times |
· B1 – public health interest
[10], population effects
[19], prevention
[19,28], prevention of ill health
[44], social impact
[13,22,33], social benefit
[13,22,33] |
|
B2: Individual effect (medical service): 6 terms, 7 times |
· B2 – type of medical service
[10], relief/prevention of symptoms/complications of disease
[42], health gain or maintenance
[44], individual effects
[19], individual impact and benefit
[13,33], the composition of the health gain
[39] |
|
C-Impact of the disease targeted by intervention |
Number of criteria: 4 |
Number of terms: 21 |
C1: Disease severity: 2 terms, 9 times |
· C1 – severity of disease
[9,10,13,19,30,37,39,47], impact of the disease/condition on quality of life
[43] |
|
C2: Disease determinants: 2 terms, 2 times |
· C2 – determinants (the factors responsible for the persistence of the burden)
[17], characteristics of target condition
[22] |
|
C3: Disease burden: 7 terms, 13 times |
· C3 – burden of disease
[9,13,22,33], disease burden
[17,25,45,48], burden of illness
[22], burden of therapy
[22], cost to treat disease
[33], cost to prevent disease
[33], national cost of the disease/condition to the healthcare system
[43] |
|
C4: Epidemiology: 10 terms, 16 times |
· C4 – prevalence
[9,13], number of potential beneficiaries
[35,37,40], indirect beneficiaries
[40], size of population
[10,19], prevalence and incidence of disease
[23,25,43], number of residents benefiting
[44], number of clients served
[43], number of patients
[47], social/demographics
[22], incidence
[22] |
|
D-Therapeutic context of intervention |
Number of criteria: 4 |
Number of terms: 18 |
D1: Treatment alternatives: 5 terms, 13 times |
· D1 – treatment alternatives
[13,22], availability of alternatives
[16,19,25,42,44,47], availability of effective intervention and preventable
[13], alternatives
[35,40,45], benchmark comparators
[16] |
|
D2: Need: 8 terms, 16 times |
· D2 – comparative interventions limitations (unmet needs)
[10], need
[19,22,28,38,42,44,49], clinical impact (need and trends)
[24], emergencies and need
[13], apparent need
[14], clinical need
[36,41,50], desirability of effects
[40], meets patient’s basic need
[38] |
|
D3: Clinical guidelines & practices: 4 terms, 7 times |
· D3 – evidence-based guidelines
[13,33,36], best practice
[14], clinical guidelines
[10,23], academic health center research (establishing/or using best practice)
[24] |
|
D4: Pre-existing use: 1 term, 1 time |
· D4 – pre-existing prescribing of the drug
[47] |
|
E-Economic impact of intervention |
Number of criteria: 9 |
Number of terms: 36 |
E1: Cost: 3 terms, 11 times |
· E1 – cost per patient
[19], costs
[19,20,22,27,32,42,44,47,51], unit cost
[22] |
|
E2: Budget impact: 6 terms, 11 times |
· E2 – budget impact on health plan
[10,19,25,47], total budget impact
[30], budget impact
[32,45,47], usage and cost implications of competing new drugs if approved
[16], affordability
[25], operating and start-up costs
[43] |
|
E3: Broad financial impact: 7 terms, 7 times |
· E3 – impact on other spending
[10], financial impact on government
[13], economic impact
[45], economics
[22], national medical costs per-year
[39], cost-saving
[33], national saving in costs of absence per year
[39] |
|
E4: Poverty reduction: 1 terms, 3 times |
· E4 – positive poverty reduction
[13,30,37] |
|
E5: Cost-effectiveness: 5 terms, 23 times |
· E5 – cost-effectiveness
[9,10,13,14,17,20,22,25-27,30,34,37,39,41,44], economic evaluations
[27], cost and consequences
[9,13,14,41], pharmacoeconomic analysis
[23], cost utility expressed as cost per QALY
[22] |
|
E6: Value: 2 terms, 3 times |
· E6 – value for money
[32,44], financial value
[44] |
|
E7: Efficiency and opportunity costs: 6 terms, 10 times |
· E7 – efficiency of intervention
[31], efficiency
[10,19,22,23,44], opportunity costs
[10], opportunity costs to the population/society
[16], best within available resources
[38], interdependencies
[50] |
|
E8: Resources: 5 terms, 6 times |
· E8 – resources
[17,51], variation in rate of use
[45], available resources
[13], resources implications
[50], volume of activity
[13] |
|
E9: Insurance premiums: 1 term, 1 time |
· E9 – impact on health insurance premiums
[9] |
|
F-Quality and uncertainty of evidence |
Number of criteria: 6 |
Number of terms: 34 |
F1: Evidence available: 7 terms, 9 times |
· F1 – evidence
[22,42,45], proof
[22], scientific evidence
[47], current level of knowledge
[17], time of assessment in technology development
[35], timelines of review
[45], therapy mechanism of action
[23] |
|
F2: Strength of evidence: 14 terms, 20 times |
· F2 – strength of evidence
[16,44], quality of evidence
[47], quality of data and past decisions
[47], quality of data
[22], quality
[26], validity of evidence
[10,19], related degree of knowledge certainty
[23], certainty
[48], consistency
[19,22,44], consistent
[38], completeness and consistency of reporting evidence
[10], openness
[26,44], selection of studies
[35,40], precision of treatment effect
[22] |
|
F3: Relevance of evidence: 5 terms, 8 times |
· F3 – relevance of evidence
[10,19], representativeness of users (studies vs. real world)
[35,40], level of generalization
[35,40], effectiveness in real practice
[22], evidence of effectiveness
[44] |
|
F4: Evidence characteristics: 5 terms, 7 times |
· F4 – normative characteristics of study
[35,40], choice of endpoints
[35,40], clinical trial data
[47], multiple randomized trials or meta-analysis/single randomized trial of reasonable size/small randomized trial
[42], phase II
[53] |
|
F5: Research ethics: 2 terms, 4 times |
· F5 – research ethics
[35,40], informed consent
[26,40] |
|
F6: Evidence requirements: 1 term, 1 time |
· F6 – adherence to requirement of decision making body
[10] |
|
G-Implementation complexity of intervention |
Number of criteria: 9 |
Number of terms: 57 |
G1: Legislation: 6 terms, 6 times |
· G1 – legal arrangements
[40], legislative issues
[22], medical liability
[40], human rights legislation
[23], legal implications
[45], conformity of programs
[22] |
|
G2: Organizational requirements and capacity to implement: 15 terms, 17 times |
· G2 – system requirements
[25], physical environment
[44], environment
[22,26], system capacity
[10], local capacity
[17], ability to implement
[38], implementation
[22], organization’s structure
[51], organizational burden
[49], logistics
[36], process
[28], well-organized
[38], organizational feasibility
[22,25], feasibility of delivery
[16], deliverability
[48] |
|
G3: Skills: 6 terms, 6 times |
· G3 – knowledge and skills
[51], nature of staff
[51], clinical education and training
[44], human resources availability
[17], recruitment and retention of staff
[44], attracting/retaining scarce clinical staff
[44] |
|
G4: Flexibility of implementation: 7 terms, 8 times |
· G4 – flexibility
[51], reversibility
[51], trialiability
[51], revisability
[51], ability to evaluate
[22], provision for revision/appeals
[38], engagement
[26,48] |
|
G5: Characteristics of intervention: 6 terms, 8 times |
· G5 – characteristics of intervention
[22], complexity of the intervention
[51], components of technology
[35], autonomy of the intervention
[38], autonomy
[17,26,46], convenience
[42] |
|
G6: Appropriate use: 3 terms, 3 times |
· G6 – appropriate use of intervention
[10], appropriateness
[44], appropriate setting/level of service
[43] |
|
G7: Barriers and acceptability: 3 terms, 4 times |
· G7 – acceptability
[22,48], responsiveness
[44], controversial nature of proposed technology
[45] |
|
G8: Integration and system efficiencies: 9 terms, 9 times |
· G8 – system integration (best use of elements of healthcare system)
[34], integration into local community
[44], ease of integration
[22], impact on other services
[40], links to other services
[44], compatibility
[22], reduction of the monitoring
[33], reduction of waiting list size
[33], impact
[22] |
|
G9: Sustainability: 2 terms, 4 times |
· G9 – sustainability
[23,24,26], longevity
[19] |
|
H-Priorities, fairness and ethics |
Number of criteria: 7 |
Number of terms: 55 |
H1 Population priorities: 5 terms, 5 times |
· H1 – perspective and current priority
[13], target and priority-setting
[14], known priorities
[44], population priority
[10], coverage of selected conditions
[13] |
|
H2 : Access: 10 terms, 17 times |
· H2 – population access
[10], access
[19,27,47,49], equity of access improvement
[13], access to care easier
[31,33,34], distribution and access to healthcare
[35,40], accessibility
[22,44], equity of access
[44], access to health system
[22], geographical equity
[43], timeliness of access
[43] |
|
H3 : Vulnerable and needy population: 9 terms, 11 times |
· H3 – vulnerable population
[37,38], potential victims
[40], particular social groups with high risk and/or increased vulnerability
[23], compassion for the vulnerable
[19], particularly needy/vulnerable groups
[44], age of targeted group
[13,30], maternal mortality
[13], quality of maternity care services
[13], population equity
[43] |
|
H4: Equity, fairness and justice: 12 terms, 32 times |
· H4 – equity
[8,13,14,19,22,25,27,40,44,46,48], fairness
[10,14,40,44,47], health equity
[23,26], equality
[19,26,38], distributive justice
[23,25], formal justice
[23], social justice
[23], justice
[26,46], social injustice
[40], addressing health status inequalities at a population level
[44], human integrity and dignity
[35,40], basic human rights
[35] |
|
H5 : Utility: 2 terms, 3 times |
· H5 – utility
[10,26], utilitarism
[25] |
|
H6: Solidarity: 6 terms, 8 times |
· H6 – solidarity
[19,25,26], collectivism
[26], mutuality
[26], reciprocal trust
[40], diversity
[26], cohesion
[26] |
|
H7: Ethics and moral aspects: 11 terms, 14 times |
· H7 – ethics
[14,22], ethical values
[22], values
[22], values and beliefs
[51], consistency with societal values
[22], ethical implications
[45], moral obligation to implement a technology
[35,40], rule of rescue
[25], priority to basic and necessary care
[38], moral consequence of HTA
[35,40], moral challenges related to certain components of HTA
[35] |
|
I-Overall context |
Number of criteria: 11 |
Number of terms: 83 |
|
I1: Mission and mandate of health system: 13 terms, 19 times |
· I1 – goals of healthcare
[52,53], goals
[21], beneficence
[28], non-maleficience and justice
[28], beneficence/non-maleficience
[17,26,53], strategic fit
[9,23], medical and social worth
[45], relevance
[22], present social consensus,
[17,49] consensus regarding public funding of a therapy
[17,53], government mandate
[17], national standards
[24], healthcare context positioning
[23] |
|
I2: Overall priorities: 6 terms, 6 times |
· I2 – national priorities
[45], national or board priority
[14], local and national priorities
[8], international priorities
[45], alignment with external directives
[9], strategic direction
[43] |
|
I3: Financial constraints: 8 terms, 13 times |
· I3 – budget constraints
[13,33,45], cost-containment
[42,49], budget level
[13,19,45], social economical context
[16], limited provincial health resources
[17], budget implementation challenges
[17], economic feasibility
[37], reliance of other services/sectors(on investment)
[14] |
|
I4: Incentives: 4 terms, 5 times |
· I4 – financial incentives
[28,45], organizational support
[16], donor involvement
[31], incentives for compliance
[20] |
|
I5: Political aspects: 5 terms, 7 times |
· I5 – political pressure
[13,19,45], political components
[52], politically and legally defensible decisions
[42], politics
[37], political impact
[37] |
|
I6: Historical aspects: 3 terms, 3 times |
· I6 – historical components
[52], past experiences
[16], historical budgets
[19] |
|
I7: Cultural aspects: 7 terms, 10 times |
· I7 – culture and religious convictions
[19,28,47], stigma
[28], compatibility with values
[16], challenge of social and values arrangements
[28,47], conception of certain persons or disease
[47], psychosocial implications
[34], public preference
[14] |
|
I8: Innovation: 3 terms, 3 times |
· I8 – perceived benefits of change
[16], innovativeness
[37], generation or application of knowledge
[43] |
|
I9: Partnership and leadership: 8 terms, 9 times |
· I9 – partnership and networking
[16], partnerships
[9], maintaining relationship
[42], leadership
[16], community development
[53], academic commitments: research and education
[9,23], partnership and collaboration across organizations
[43], contribution to position as a learning organization
[43] |
|
I10: Citizen involvement: 3 terms, 3 times |
· I10 – citizenship
[53], ownership
[53], enabling health literacy (empowerment)
[53] |
I11: Stakeholders interests and pressures: 23 terms, 28 times | · I11-stakeholders pressure [52], advocacy [16,45], pressure from physician and patients groups and past decisions [32], clinical expert opinions [37], patient representative group opinions [37], power relations among stakeholders [28], user of the technology interests [47], challenge the relationship between patient and physician [47], professional prestige [28,47], clinicians excitement and decisions in other hospitals [32], public reaction and public accountability [28], HTA’s producer interest [28,47], company activities [32], researchers ethics interests [28,47], third party agents involved [47], recommendations made by other countries [13], status in other jurisdictions [49], current status of public funding in other jurisdictions [17], drugs used in other hospitals [32], expressed demand [14,37], patient demand [32], expected level of interest (patient and medical) [34], entitlement [28] |
This table is reporting all the terms (338) extracted from the selected articles and tabulates them using the classification system developed for this study, which is based on a hierarchical approach clustering 58 criteria into 9 categories.